Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Zydus"

348 News Found

Zydus wellness reports 31% growth in net sales in Q2 FY26
News | November 06, 2025

Zydus wellness reports 31% growth in net sales in Q2 FY26

During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries


Zydus receives FDA’s ODD for Desidustat for the treatment of beta-thalassemia
Drug Approval | November 06, 2025

Zydus receives FDA’s ODD for Desidustat for the treatment of beta-thalassemia

Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval


Zydus receives FDA’s tentative approval for Budesonide delayedrelease capsules, 4 mg
Drug Approval | November 05, 2025

Zydus receives FDA’s tentative approval for Budesonide delayedrelease capsules, 4 mg

Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and olde


Zydus Wellness appoints Manish Lal as Head, Global Demand and Supply Organization
People | November 02, 2025

Zydus Wellness appoints Manish Lal as Head, Global Demand and Supply Organization

With over two decades of extensive experience, Lal has established himself as a transformational leader in the FMCG and consumer goods sectors


Zydus receives approval from Health Canada for Mesalamine suppositories
News | October 27, 2025

Zydus receives approval from Health Canada for Mesalamine suppositories

Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis


Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg
Drug Approval | October 07, 2025

Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg

Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ


FDA approves Zydus’ Deflazacort oral suspension, 22.75 mg/mL
Drug Approval | October 07, 2025

FDA approves Zydus’ Deflazacort oral suspension, 22.75 mg/mL

Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older


Zydus, Pinkathon to drive awareness on breast cancer across India
Healthcare | September 24, 2025

Zydus, Pinkathon to drive awareness on breast cancer across India

Zydus Pinkathon will be led by women to raise awareness on breast cancer and women's health


Zydus receives EIR for oncology injectable manufacturing facility in Ahmedabad SEZ1
Drug Approval | September 24, 2025

Zydus receives EIR for oncology injectable manufacturing facility in Ahmedabad SEZ1

The facility has been classified as Voluntary Action Indicated


Zydus Lifesciences appoints Nitin Parekh as President (Special Projects)
People | September 08, 2025

Zydus Lifesciences appoints Nitin Parekh as President (Special Projects)

He has been associated with the Zydus Group since 2009